

Index

A

absolute risk 41, 63, 96
 absolute risk difference 98
 abstracts in published studies
 observational studies 198
 randomized trials 186, 190
 structured, example 203
 academic stream, authorship 173–176, 214
 accuracy 90, 221
 actuarial life tables 155–156
 adaptive response method 15
 adjudication committee 34–36, 214
 adjudication of outcomes 34–37, 36
 defined 35, 214
 web-based 37
 administrative censoring 149
 adverse event 46, 214
 allocation
 comparison of schemes 20
 concealment 19, 23–24, 184
 envelope, temptations 24
 ratio 18–19
 see also patient allocation
 alpha spending function 164–165
 alpha (α) (type I) error 140, 163
 alternative hypothesis 162, 214
 applicability, trial results 10, 214
 arms, in trial 18
 assessor, independent 11
 associations
 observational vs. causal 136
 and regression analysis 144
 audience, and authorship 174, 176, 178, 180
 author, defined 173, 214
 authors, and publication bias 115
 authorship 173–182
 contributions 174, 177, 179, 181
 see also reporting guidelines

B

bait and switch 32
 b and beta (β) 150, 214
 baseline characteristics 5
 beta (β) (type II) error 140
 bias 61, 194, 205, 214
 censoring 32
 clinical 31
 confounding 126
 vs. confounding variables 194
 defined 9
 due to expertise, overcoming 8
 sampling 198–199
 selection 1, 10, 128, 220

see also publication bias
 binary outcome 98, 214
 blind 10, 44, 214
 blinding 23–27, 24–26, 187
 levels 25–26
 in surgical trials 23
 block randomization 4, 16–17, 20, 186–187, 214

C

case-cohort study, nested 55, 218
 case-control studies 52–58, 62
 within cohort study 55
 definition 52–53
 methodology 53–55
 nested 55, 62, 218
 retrospective 128–129
 case series 129
 cases, selecting 53
 censoring
 administrative 149
 right 154
 survival data 154
 censoring bias 32
 central methods center 47, 48, 214
 see also methods center
 central outcomes adjudication
 committee 47, 48, 49
 checklists
 CLEAR NPT 189
 CONSORT Statement 184–185
 MOOSE 205–207
 randomized trials 183–192
 STROBE Statement 64, 195–196
 CLEAR NPT 141, 183–184, 191
 checklist 189
 clinical bias 31, 214
 clinical trials, phases 44–45
 closed-ended questions 67, 68, 214
 clustering effect 190
 Cochrane Collaboration (Database/
 Library/Register) 92, 103, 189
 see also Review Manager (RevMan)
 Cochrane Handbook 106, 107
 Cochran's Q 127
 coding 77, 79, 214
 Cohen's *d* 96, 97
 cohort studies 59–65
 design types 62–63
 prospective 128
 committees 35, 36, 48–49
 comparisons, across studies 96
 composite outcomes 28, 215
 advantages 30
 disadvantages 31
 guidelines 31–32
 limitations 30–31
 in orthopaedics 28–33
 rationale 29–30
 reporting and interpreting 32
 see also outcomes
 Comprehensive Meta-Analysis (CMA)
 123, 124
 concealment 19, 23–27, 184
 conditional logistic regression 56, 215
 conditional probability 156
 confidence intervals, for effect sizes 99
 conflict of interest
 defined 168, 215
 legal implications 169
 reporting 168–172
 types 170
 confounders 60–61, 188, 215
 adjustment for 148
 confounding 23, 145
 vs. bias 194
 reducing 63
 residual 130, 219
 confounding bias 126
 consecutive sampling 198, 214
 CONSORT group 5, 214
 CONSORT guidelines 5, 141, 188
 CONSORT Statement 5, 95, 183–184, 215
 checklist 184–185
 flow diagram 187
 NPT extension 190–191
 constant comparison method 78–80
 construct validity 69, 70, 215
 contamination 190, 191, 215
 content validity 69, 70, 215
 contract research
 organizations 212–213
 controlled vs. observational
 studies 62
 controls, selecting 53
 see also case-control studies
 convenience sampling 198
 cost analysis 84
 cost-benefit analysis 85
 cost data, reliability 88
 cost-effectiveness analysis 84
 cost-effectiveness ratio 82, 83, 84, 215
 cost-utility analysis 84–85
 courses, surgical research 211–212
 covariate adaptive randomization 15
 covariates 135, 136, 137, 145, 151, 152, 217
 Cox regression 158–159
 Cronbach's alpha (α) 69
 crossover 9, 19, 215
 cross-sectional studies 193
 cumulative hazard function 160
 cumulative probability 156

- D**
- data and safety monitoring board (DSMB) 35, 36, 215
 - data dredging 102, 128, 137
 - data extraction,
 - literature searches 93–94
 - data management 139, 215
 - data monitoring committee 49, 215
 - and interim analysis 165
 - data pooling 127
 - fixed vs. random effects 102–103
 - see also statistical pooling
 - data safety and monitoring board 140, 165
 - data tables 141
 - deductive method 75, 215
 - delta (δ) (minimum clinically important difference) 140
 - dependent variable 55, 145, 215, 218
 - DerSimonian and Laird method 103
 - diagnostic suspicion bias 194, 215
 - differential expertise bias 8, 9, 10, 215
 - disclosure
 - of conflicts of interest 168, 169, 170–171
 - of data by staff 142
 - discounting of costs 87
 - discussion section in published studies
 - observational studies 200
 - randomized trials 188, 191
 - distortion, due to publication bias 115
 - dummy variable 147, 148, 215
- E**
- economic analysis 82–89
 - educational stream,
 - authorship 176–178, 216
 - effect sizes 95–101, 216
 - confidence intervals 99
 - continuous outcomes 97
 - noncontinuous outcomes 97–98
 - Egger's linear regression method 115
 - electronic surveys 71–72
 - EMBASE 92
 - end point 28, 34, 216
 - see also composite outcomes
 - end product assessment (EPA) score 145, 146, 147
 - envelope allocation 24
 - EQUATOR network 202
 - equipoise 9, 46, 216
 - equivalence, perceived 12
 - ethical considerations
 - misconduct 168
 - research 46, 162
 - in surveys 72
 - ethnography 77, 216
 - evidence-based medicine 34, 59, 75, 77, 183, 216
 - evidence, strengthening 64
 - expertise-based randomized trials 8–13
 - expertise bias 8, 9, 10, 215
 - exploratory analysis 188
 - exposure suspicion bias 194, 216
 - external validity 10, 194–195, 216
- F**
- factorial RCTs 1–7, 216
 - design 2–4
 - selecting 3–6
 - fail-safe N 116
 - failure curve 156, 157, 158, 159
 - failure function 156, 158, 216
 - false-positive results 30, 163
 - family information bias 194, 216
 - fax surveys 71
 - financial interests, disclosure 170–171
 - fit, goodness of 152
 - fitting 151
 - fixed effects
 - analysis 135, 216
 - vs. random effects 102–105
 - fixed-effects regression 108–109, 216
 - fixed nominal level approach 163
 - flow diagram
 - for case–control study 197
 - CONSORT statement 187
 - PRISMA checklist 203, 205
 - forest plot 119, 127, 128, 216
 - Four Greeks and Four Others 140
 - four streams of authorship 173
 - funding 49–50
 - and conflicts of interest 168
 - funnel plot 115, 119, 216
- G**
- Glass's Δ 96, 97
 - glossary of terms 214–221
 - goodness of fit 152
 - graduate programs 209–210
 - grounded theory 76, 77, 216
 - group sequential method 163–164
 - guidelines
 - for composite outcomes 31–32
 - on disclosure 170
 - on reporting 141
 - subgroup interpretation 42
 - see also checklists; reporting checklists
- H**
- Haybittle–Peto method,
 - interim analysis 163, 164
 - hazard function 156, 216
 - cumulative 160
 - hazard ratio 159–160, 216
 - health economics 83
 - conducting studies 85–88
 - Hedges' g 96, 97
 - heterogeneity 106–113, 128, 206, 216
 - clinical vs. statistical 102
 - dealing with 107–110
 - identifying 107
 - and meta-regression 132–133
 - qualitative 30, 31, 219
 - quantitative 30, 219
 - of studies 120
 - hypothesis 217
 - alternative 162
 - null 162
- I**
- I^2 statistic 107, 127–128, 217
 - incident cases 53, 217
 - independent variable 145, 217
 - inductive method 75, 217
 - industrial stream,
 - authorship 178–180, 217
 - industry collaboration,
 - and conflicts of interest 168–172
 - industry-initiated trials 46–47
 - industry-initiated
 - vs. investigator-initiated 44, 217
 - information bias 61
 - information fraction 164–165
 - intention-to-treat analysis 188, 217
 - interactions
 - defined 5, 217
 - and study design 4, 5
 - interim analyses
 - in randomized trials 162–167
 - in statistical planning 140–141
 - internal validity 9, 62, 217
 - interventions 1, 217
 - multiple 2
 - timing 19
 - see also treatment
 - introduction sections in published studies
 - observational studies 198
 - randomized trials 186
 - investigator-initiated trials 47–48
- J**
- journals, as resources 210–211
- K**
- Kaplan–Meier method 155, 157–160
- L**
- L'Abbé plot 134, 135, 217
 - life tables, actuarial 155–156
 - linear regression 145–147
 - literature searches 90–94
 - steps 91
 - transparency 94
 - vocabulary terms 92
 - logistic regression 147–149, 217
 - conditional 56, 215
- M**
- mail surveys 71
 - Mantel–Haenszel method 103
 - Markov analysis 86, 87
 - matching 56, 198, 217

- matrix table 5
 measurement bias 194
 media, popular 180–182, 218
 MEDLINE 92
 membership bias 194, 217
 mentorship 209
 meta-analyses 91, 217
 data sources 202
 and effect size 99–101
 flow diagram 203, 205
 observational studies 126–131
 output 120
 programs 122
 reporting checklists 202–208
 Meta-Analysis in Excel (MIX)
 program 122–123, 124
 Meta-Analyst, program 122, 124
 meta-regression 109, 132–138, 217
 interpreting 135–136
 limitations 137
 mechanics 133–135
 methodological quality, assessing 93
 methods center 35, 47, 48, 214, 217
 methods section in published studies
 observational studies 198
 randomized trials 186, 190
 minimization 17, 20–21, 217
 minimum clinically important
 difference (MCID) 140
 MIX, statistical program 122–123, 124
 model building 151–152
 model fitting 151–152
 MOOSE checklist 205–207
 multiple testing 30, 217–218
 multiplicity 40
 multivariate/multivariable regression
 152, 218
- N**
- negative studies 114, 218
 nested case-cohort study 55, 218
 nested case-control study 55, 62, 218
 new treatment, economic analysis 86
 nonpharmacological trials (NPTs) 184,
 188–189
 nonprobability sampling 198
 nonrespondent bias 194, 218
 null hypothesis 162, 218
- O**
- O'Brien-Fleming method, interim
 analysis 163, 164
 observational data 126–127
 vs. causal associations 136
 types 128–130
 observational studies
 vs. controlled studies 62
 designs 193
 meta-analysis 126–131
 reporting checklists 193–201
 odds 147, 218
 odds ratio 53, 54, 56, 98
 online courses 210
- open-ended questions 67, 68, 218
 ordinal scales 68, 218
 orthopaedics,
 composite outcome in 28–33
 outcome measures
 and blinding 25
 in observational study designs 193
 statistical program input 120
 and utility value calculation 88
 outcomes 34, 218
 adjudication 34–38
 ascertainment 32, 34, 218
 composite *see* composite outcomes
 rare 54
 outcomes adjudication
 committee 47, 48, 49
 outcome variable 34, 140, 145, 215, 218
 output, meta-analysis 120
 overfitting 151
 overmatching 56, 218
- P**
- parallel randomized trials 2
 participants 195
 patient allocation 15–21
 deterministic 15
 random 15–18
 see also allocation; recruitment
 patient characteristics, reporting 197
 Peto method, interim analysis 163, 164
 phases, of clinical trials 44–45
 phenomenology 77, 218
 PICO model 91, 92
 pilot testing, surveys 70
 planning, statistical analysis 139–143
 Pocock and Simon method,
 minimization 17
 Pocock method,
 interim analysis 162, 163, 164
 pooled estimate differences 103–104
 pooling *see* data pooling; statistical
 pooling
 popular media stream,
 authorship 180–182, 218
 positive studies 114, 218
 power, statistical 41
 predictor 144, 145, 152, 217
 prespecification,
 meta-regression covariates 137
 prevalence-incidence bias 194, 218
 prevalent cases 53, 218
 PRISMA checklist 203, 204–205, 206
 probability, conditional
 vs. cumulative 155–156
 probability sampling 198
 prognostic factors 18
 programs, statistical pooling 120–123
 comparison table 124
 proportional hazards 160
 proportional hazards regression 149–152
 prospective vs. retrospective studies 64
 publication bias 119, 218
 minimizing effect of 116
 uncovering 114–117
- publications, style and authorship 174,
 176, 178, 180
 purposive sampling 78, 219
 P value 95–96, 219
- Q**
- qualitative heterogeneity 30, 31, 219
 qualitative studies 75–81
 vs. quantitative studies 76
 steps 78–80
 quality-adjusted life years 82, 84, 88
 quantitative heterogeneity 30, 219
 quantitative studies,
 vs. qualitative studies 76
 question development 67–68
 literature searches 92
 questionnaire *see* survey
 QUOROM statement 119, 203
- R**
- random-effects analysis 135, 219
 random-effects regression 109, 219
 random effects,
 vs. fixed effects 102–105
 randomization 20, 45, 219
 block 4, 16–17, 20
 inappropriate methods 183
 mechanics 19–21
 simple 16, 20
 stratified 17, 20, 40–41
 systems and technology 14–22
 timing of 10, 19
 unit 18
 randomized controlled trials (RCTs)
 conventional 8–9
 defined 1, 9, 219
 design strategies 2–3
 expertise-based 9–13
 factorial 1–7
 interim analyses 162–167
 new treatment combination
 vs. control 2–3
 parallel 2
 quality 183
 reporting checklists 183–192
 sequential 2
 stopping early 166–167
 rank correlation test 115
 rare outcomes 54, 56
 RCT *see* randomized controlled trials
 recall bias 53, 61, 194, 219
 receiver-operating characteristic
 (ROC) curve 120, 219
 recruitment of patients 9, 12, 18–19
 period 19, 154, 187
 for phase I trials 44
 progress reporting 140, 141
 redundancy 78, 219
 reflexivity 75, 219
 regression 144–152
 see also linear regression; logistic
 regression; proportional hazards
 regression

- regression coefficients 136
 regression model 119, 219
 relative risk 41, 63, 96
 reliability 69, 70, 219
 replication 41–42
 reporting checklists
 meta-analyses 202–208
 observational studies 193–201
 randomized trials 183–192
 reporting guidelines 141
 required output 120
 research,
 contract organizations 212–213
 research question
 aligned to outcome 28, 31
 developing 67, 78, 80
 identifying 67, 73
 and study design 10
 see also study question
 residual confounding 130, 219
 response adaptive method 15
 response bias 69, 70, 219
 responsiveness 69, 70, 219
 results section in published studies
 observational studies 199
 randomized trials 187–188, 190–191
 retrospective vs. prospective studies 64
 Review Manager
 (RevMan) 103, 122, 124
 right censoring 154
- S**
- sample identification 67
 sample size calculation 4, 140, 186, 220
 and allocation strategy 18
 for detecting interaction 5
 sampling
 purposive 77, 78
 strategies 198
 sampling bias 194
 saturation 78, 220
 screening pool 11–12
 selection bias 1, 10, 128, 220
 selection criteria 197
 sensitivity 10, 70, 120, 220
 sensitivity analysis 87–88, 116, 141, 220
 sequential randomized trials 2
 sigma (σ) (standard deviation) 140
 simple random sample 198, 220
- software
 listing for SAP 141
 survival analysis 161
 specificity 10, 70, 120, 220
 standardized mean difference 96, 97, 220
 Stata/WinBUGS 123, 124
 statistical analysis plan (SAP) 139–143
 literature 141
 survival analysis 161
 statistical pooling 93, 106, 118–125, 220
 programs 120–123
 see also data pooling
 statistical power 41, 186
 statistical procedures 139–140
 steering committee 35, 36, 48–49, 220
 stopping early,
 randomized trials 166–167
 stratification 4, 186, 220
 stratified sampling 198
 streams of authorship 173
 strengths and weaknesses, analysis 88
 STROBE Statement 194–197
 checklist 64, 195–196
 explanations of
 checklist items 197–200
 how to use 197
 study question 1, 10, 220
 see also research question
 style, and authorship 174, 176, 178, 180
 subgroup analyses 39–43, 109
 defined 39, 220
 surgical research, resources 209–213
 survey administration 70–72
 survey design 66–74
 features of good survey 69, 70
 financial considerations 72
 survey validation 69–70
 survival analysis 153–161
 methods 155–160
 survival curve 156, 157, 158
 survival data, censoring 154
 survival function 156, 220
 systematic reviews 90, 126, 220
 systematic sampling 198, 220
- T**
- tables for presentation 141
 target variable 34, 215, 218
 telephone surveys 71
- testing, multiple 30
 textbooks, as resources 210–211
 theoretical sampling 78
 time-to-event data 154–155
 time-to-event studies, design 160–161
 timing of randomization 10, 19
 titles in published studies
 observational studies 198
 randomized trials 186–186, 190
 traditional review 90, 220
 transparency, literature searches 94
 treatment effect 95, 221
 magnitude 95–96
 treatments, new
 vs. control 2–3
 economic analysis 83, 86
 see also interventions
 trial management 44–51
 trial registers 116–117
 triangulation 76, 77, 78, 79, 221
 trim and fill method 115–116
 type I error 40, 140, 163, 165, 221
 type II error 41, 140
- U**
- univariate regression 152, 221
 unmasking bias 194, 221
 utilities 82, 84, 221
 calculating 88
- V**
- validity 221
 external 10, 194–195, 216
 internal 9, 217
 literature reviews 90
 variable
 dependent vs. independent 145
 dummy 147, 148
 vocabulary terms, in literature
 searches 92
- W**
- workshops, surgical research 211–212
 writing *see* authorship; reporting
 guidelines